Federico Colombo
About Federico Colombo
Federico Colombo is a scientist specializing in in vitro pharmacology with a focus on oncology. He currently works at Mythic Therapeutics, Inc. and has extensive research experience, including contributions to clinical studies and scientific publications.
Work at Mythic Therapeutics
Federico Colombo currently serves as a Scientist in In Vitro Pharmacology at Mythic Therapeutics, Inc. since 2022. His role involves conducting research and development in the field of pharmacology, specifically focusing on drug therapies. The company is located in Waltham, Massachusetts, and is known for its innovative approaches to cancer treatment.
Education and Expertise
Federico Colombo has a robust educational background in biological sciences and pharmacology. He earned a Bachelor of Science in Biology from Università degli Studi dell'Insubria from 2006 to 2009, followed by a Master of Science in Biology from the same institution from 2009 to 2012. He further advanced his studies by obtaining a Doctor of Philosophy in Molecular Medicine from Libera Università Vita-Salute San Raffaele between 2013 and 2017. His expertise spans scientific communication, oncology, and pharmacology.
Background
Colombo has accumulated over 10 years of research experience in oncology and pharmacology. He has worked as a post-doctoral researcher at The Ohio State University College of Pharmacy since 2018. Prior to this, he completed a Board Certified MSL training program at SCIENCE to PHARMA in Columbus, Ohio, from 2020 to 2021, which enhanced his skills in scientific communication and medical science liaison roles.
Achievements
Federico Colombo has contributed to significant research initiatives, including a Phase 1 multicenter dose escalation and dose expansion study of MYTX-011, a pH-dependent anti-cMET antibody-drug conjugate. He co-authored a journal article on this subject and has presented research at notable conferences, including the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and the American Association of Cancer Research (AACR) Annual Meeting.